ArticleJHEP reports : innovation in hepatology2026
FASN-dependent lipogenesis controls macrophage efferocytosis in alcohol-associated liver disease.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsDefective clearance of apoptotic hepatocytes contributes to inflammation of the liver and progression of alcohol-associated liver disease (ALD), but mechanisms regulating macrophage efferocytosis during alcohol exposure remain unclear. We investigated whether fatty acid synthase (FASN)-dependent lipid metabolism controls hepatic macrophage efferocytosis in ALD.
methodsHuman liver tissues from patients with alcohol-related cirrhosis (AC) and controls (n = 18 per group), together with experimental ALD mouse models (six per group), were analyzed for hepatocyte apoptosis and hepatic macrophage alterations. Transcriptomic profiling (three per group), pharmacological inhibition, and myeloid- or Kupffer cell-specific Fasn knockout mice (six per group) were used to define the role and mechanism of FASN-mediated lipogenesis in macrophage efferocytosis.
resultsIn patients with AC, hepatocyte apoptosis and accumulation of CD68-positive inflammatory macrophages were significantly increased compared with controls (p <0.0001). In experimental ALD mice, hepatocyte apoptosis and monocyte-derived macrophage infiltration were also significantly increased (p <0.0001). Mechanistically, ethanol impaired macrophage efferocytosis by >80% (p <0.01). This was associated with inhibition of the PI3K/AKT/SREBP1 pathway, reduced FASN expression, and suppressed de novo lipogenesis. Reduced FASN expression decreased NRF2 activity and impaired TREM2 transcription, resulting in defective clearance of apoptotic cells. TREM2-positive hepatic macrophages were significantly decreased in patients with AC and experimental ALD mice (p <0.0001). Consistently, Kupffer cell-specific Fasn deletion significantly aggravated hepatocyte apoptosis and liver injury in vivo (p <0.01).
conclusionsAlcohol impairs macrophage efferocytosis by suppressing the PI3K/AKT/SREBP1-FASN-NRF2-TREM2 axis. Disruption of this lipogenic program promotes hepatocyte apoptosis and liver inflammation in ALD. IMPACT AND IMPLICATIONS: Alcohol-associated liver disease is characterized by hepatocyte death and ongoing inflammation, but mechanisms that connect these processes to macrophage efferocytosis remain poorly understood. In our research, we found that ethanol suppresses FASN-dependent de novo lipogenesis and downstream NRF2-TREM2 signaling in hepatic macrophages. Impairment of lipogenesis compromises efferocytosis, leading to accumulation of apoptotic hepatocytes and increased monocyte infiltration. These findings underscore the potential of targeting macrophage lipid metabolism as a therapeutic strategy in ALD. However, further translational validation is needed before clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.